Download original image
Fig. 4. Group mean (n=5 per drug and dose condition) BPND parametric images comparing changes in [123I]FP-CIT BPND in the striatum (A) and midbrain (B) after treatment with BUP, HAL and CLZ. These changes are also summarized in graphs (C). VEH, BUP, HAL and CLZ represent the vehicle-, bupropion-, haloperidol- and clozapine-treated groups. The low and high doses of HAL, CLZ and BUP were 1 and 7 mg/kg body weight, 10 and 54 mg/kg body weight, and 20 and 100 mg/kg body weight, respectively. Values are the mean±SEM. White lines overlaid on the SPECT images of the striatum (A) and midbrain (B) for the vehicle-treated group show the margin of each region.|@|~(^,^)~|@|Time course of the effects of HAL (A) and CLZ (C) treatment on DA release in the rat striatum (n=5 per drug and dose condition). Time-averaged (from the time of drug treatment to the end of the study) percentage changes from baseline for each dose of HAL (B) and CLZ (D). HAL and CLZ represent the haloperidol- and clozapine-treated groups. The low and high doses of HAL and CLZ were 1 and 7 mg/kg body weight and 10 and 54 mg/kg body weight, respectively. The value is designated as 0% at time 0, and drugs were treated at time=0 min. Values are the mean±SEM.|@|~(^,^)~|@|Relationship between percentage differences in [123I] FP-CIT BPND (x-axis) and time-averaged percentage changes from baseline extracellular DA concentration (y-axis) after treatment with varying doses of HAL and CLZ. HAL and CLZ represent the haloperidol- and clozapine-treated groups. The low and high doses of HAL and CLZ were 1 and 7 mg/kg body weight and 10 and 54 mg/kg body weight, respectively. Values are the mean±SEM.
Experimental Neurobiology 2019;28:602~611 https://doi.org/10.5607/en.2019.28.5.602
© Exp Neurobiol